Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.37 |
| ▸ | CDK4 | P11802 | 3/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27259965 | 0.83 | CSF1R (0.38) | CSF1RCDK4CDK6PIK3CDPKM | |
| SCHEMBL16404598 | 0.81 | HTR6 (0.40) | CSF1RCDK4CDK6PIK3CDPKM | |
| SCHEMBL21245567 | 0.80 | CDK4 (0.41) | CSF1RCDK4CDK6PIK3CDALDH1A1 | |
| SCHEMBL21245641 | 0.80 | CDK6 (0.43) | CSF1RCDK4CDK6PIK3CD | |
| SCHEMBL20719131 | 0.80 | PTGER3 (0.40) | CSF1RCDK4CDK6PIK3CDLMNA | |
| SCHEMBL13036606 | 0.78 | TDP1 (0.40) | CSF1RCDK4CDK6PIK3CDPKM | |
| SCHEMBL13075588 | 0.78 | CDK4 (0.36) | CSF1RCDK4CDK6PIK3CDPKM | |
| SCHEMBL23407701 | 0.77 | NOTUM (0.48) | LMNACYP11B2RIPK1 | |
| SCHEMBL21245553 | 0.76 | CDK4 (0.43) | CSF1RCDK4CDK6PIK3CDLMNA | |
| SCHEMBL27358451 | 0.76 | NPC1 (0.45) | CSF1RCDK4CDK6PIK3CDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-112334451-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3752491-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019161224-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | GiraFpharma LLC (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | CSF1R 3721/4885CDK4 2/4885CDK6 1/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CSF1R 4272/4885CDK4 1/4885CDK6 2/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CSF1R 4272/4885CDK4 1/4885CDK6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.